Commonly occurring loss and mutation of the MXI1 gene in prostate cancer

✍ Scribed by Edward V. Prochownik; Linette Eagle Grove; Debra Deubler; Xiao Lin Zhu; Robert A. Stephenson; L. Ralph Rohr; Xiaoying Yin; Arthur R. Brothman

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 341 KB
• Volume: 22
• Category: Article
• ISSN: 1045-2257
• DOI: 10.1002/(sici)1098-2264(199808)22:4<295::aid-gcc5>3.0.co;2-q

✦ Synopsis

One of the most common chromosomal abnormalities in prostate cancer involves loss of 10q22-qter. Rarely, a smaller deletion, involving 10q24-q25, has been observed, suggesting the presence of a tumor suppressor gene at this site. We previously demonstrated that the MXI1 gene maps to 10q24-q25 and is mutated in some tumors with cytogenetically detectable deletions of this locus. MXI1 encodes a basic-helix-loop-helix protein that suppresses the transcriptional activity of the MYC oncoprotein by competing for the common dimerization partner, MAX, and binding to identical DNA sites. Because more than 90% of prostate tumors contain no cytogenetic abnormality of 10q, the relevance of MXI1 loss and/or mutation to the vast majority of cases remains unclear. We prospectively evaluated prostate tumors for loss of MXI1 by fluorescence in situ hybridization (FISH) and cytogenetic techniques. Twenty-one of 40 tumors (53%) demonstrated loss of a single MXI1 allele as determined by FISH. Ten cases with cytogenetically normal 10qs, but with FISH-documented deletion of MXI1, were examined at the molecular level, and eight mutations were identified, albeit at low frequency. Five of the mutant proteins were unable to bind DNA in association with MAX. We conclude that MXI1 gene loss in prostate cancer is common and most frequently involves a cytogenetically undetectable deletion.